Loading...
SMO mutations confer poor prognosis in malignant pleural mesothelioma
BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pat...
Na minha lista:
| Udgivet i: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7653142/ https://ncbi.nlm.nih.gov/pubmed/33209614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-19-425 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|